Ricinoleic Acid stearyl Ester | 93980-70-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Ricinoleic Acid stearyl Ester
• 英文别名: Octadecyl ricinoleate；octadecyl (Z,12R)-12-hydroxyoctadec-9-enoate
• CAS: 93980-70-2
• 化学式: C₃₆H₇₀O₃
• 分子量: 550.95
• InChiKey: PHVQRWNQGOIZLC-YZPCPXFJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.9
• 重原子数：
  39
• 可旋转键数：
  33
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Polymeric formulations for drug delivery
  申请人：Efrat Biopolymers Ltd.

  公开号：US20040161464A1

  公开（公告）日：2004-08-19

  Poly(ester-anhydrides) or polyesters formed from ricinoleic acid and natural fatty diacids and their method of preparation and its use for delivering bioactive agents including small drug molecules, peptides and proteins, DNA and DNA complexes with cationic lipids or polymers or nano and microparticles loaded with bioactive agents are disclosed herein. The drug delivery compositions are administered to a patient in a liquid form, increase in viscosity in vivo to form a drug depot or implant, and are able to release the incorporated bioactive agent for weeks. In the preferred embodiment, the drug delivery formulations are administered by injection. In one embodiment, the compositions are suitable for local or regional delivery of drugs to diseased sites, such as treating solid tumors and bone infections. In a preferred embodiment, the drug delivery compositions are suitable for site-specific chemotherapy for the treatment of solid tumors including: squamous cell carcinoma (SCC) of the head and neck, prostate cancer, and sarcomas for intratumoral injection or insertion.

  本文公开了由蓖麻油酸和天然脂肪二酸形成的聚酯酸酐或聚酯以及它们的制备方法，以及它们用于输送生物活性剂，包括小分子药物、肽和蛋白质、DNA和带阳离子脂质或聚合物或纳米和微粒子的DNA复合物。这些药物输送组合物以液态形式给患者使用，在体内粘度增加形成药物库或植入物，并能够持续释放所包含的生物活性剂达数周之久。在首选实施例中，药物输送配方通过注射给予。在一个实施例中，该组合物适用于将药物局部或区域性输送到疾病部位，例如治疗实体肿瘤和骨感染。在首选实施例中，药物输送组合物适用于针对实体肿瘤的特定部位化疗，包括头颈鳞状细胞癌（SCC）、前列腺癌和肉瘤的肿瘤内注射或插入。
• Polyanhydrides
  申请人：——

  公开号：US20040057970A1

  公开（公告）日：2004-03-25

  The invention provides polyanhydrides with aliphatic hydrocarbon terminals having ester or amide bonds.

  该发明提供了具有酯或酰胺键的脂肪族碳末端的聚酸酐。
• Bactericide against vancomycin resistant enterococcus
  申请人：Iwai, Kazuo

  公开号：EP1190715A1

  公开（公告）日：2002-03-27

  The present invention provides a method of sterilizing VRE using a composition which contains hinokitiol, a metal complex thereof or their salt as an effective component, and aloe extract and the like extracts as preferably used. The composition is administered to an animal infected with VRE, or a site contaminated with VRE.

  本发明提供了一种使用组合物对 VRE 进行灭菌的方法，该组合物含有作为有效成分的桧 基硫醇、其金属络合物或它们的盐，以及优选使用的芦荟提取物和类似提取物。该组合物用于感染 VRE 的动物或被 VRE 污染的场所。
• ANTIPERSPIRANT COMPOSITION
  申请人：Johnson & Johnson Consumer Inc.

  公开号：EP3034131A1

  公开（公告）日：2016-06-22

  The present invention relates to a topical antiperspirant composition comprising a cosmetically acceptable topical carrier and an anticholinergic agent selected from the group consisting of acetyl octapeptide-3 and dipeptide diaminobutyroyl benzylamide diacetate in an amount effective to inhibit or prevent perspiration, wherein said composition is substantially free of aluminum salts.

  本发明涉及一种局部止汗剂组合物，该组合物包含化妆品可接受的局部载体和一种抗胆碱能剂，该抗胆碱能剂选自乙酰八肽-3 和二肽二氨基丁酰基苄酰胺二乙酸酯组成的组，其用量可有效抑制或防止出汗，其中所述组合物基本上不含铝盐。
• ANTIPERSPIRANT FORMULATION CONTAINING NON-ALUMINUM METAL AND ESSENTIAL OIL
  申请人：Gulbrandsen Technologies, Inc.

  公开号：EP3563824A1

  公开（公告）日：2019-11-06

  Provided is an antiperspirant formulation containing antiperspirant active ingredients, a solvent, and an additive, wherein the antiperspirant active ingredients comprise an essential oil and a non-aluminum metal, wherein the essential oil comprises mentha arvensis oil, eucalyptus globulus oil or a mixture thereof, and the non-aluminum metal comprises zinc, calcium, magnesium or a mixture thereof.

  本发明提供了一种止汗剂配方，其中含有止汗剂活性成分、溶剂和添加剂，止汗剂活性成分包括精油和非铝金属，其中精油包括薄荷油、桉叶油或它们的混合物，非铝金属包括锌、钙、镁或它们的混合物。